2025-02-11 00:00:00
: Portfolio change date
| Asset |
Action |
Weight |
PnL |
Entry Date |
|
RGNX
REGENXBIO Inc.
|
Buy |
8.17% |
-2.23% |
2025-02-03 |
The percentage of cash held in the portfolio is:
91.83%
New Assets Added
None
Assets Removed
| Asset |
Action |
Perf % |
| AGEN |
Sell
All
|
-15.67% |
Assets Rebalanced
None
2025-02-10 00:00:00
: Portfolio change date
| Asset |
Action |
Weight |
PnL |
Entry Date |
|
AGEN
Agenus Inc.
|
Buy |
8.42% |
-8.62% |
2025-01-22 |
|
RGNX
REGENXBIO Inc.
|
Buy |
8.42% |
1.73% |
2025-02-03 |
The percentage of cash held in the portfolio is:
83.16%
New Assets Added
None
Assets Removed
| Asset |
Action |
Perf % |
| BLFS |
Sell
All
|
-7.77% |
Assets Rebalanced
None
2025-02-07 00:00:00
: Portfolio change date
| Asset |
Action |
Weight |
PnL |
Entry Date |
|
AGEN
Agenus Inc.
|
Buy |
8.93% |
-2.35% |
2025-01-22 |
|
BLFS
BioLife Solutions, Inc.
|
Buy |
9.24% |
-7.46% |
2025-01-30 |
|
RGNX
REGENXBIO Inc.
|
Buy |
8.57% |
4.46% |
2025-02-03 |
The percentage of cash held in the portfolio is:
73.26%
New Assets Added
None
Assets Removed
| Asset |
Action |
Perf % |
| ORGO |
Sell
All
|
6.61% |
Assets Rebalanced
None
2025-02-06 00:00:00
: Portfolio change date
| Asset |
Action |
Weight |
PnL |
Entry Date |
|
ORGO
Organogenesis Holdings Inc.
|
Buy |
9.68% |
8.11% |
2025-01-17 |
|
AGEN
Agenus Inc.
|
Buy |
9.24% |
1.83% |
2025-01-22 |
|
BLFS
BioLife Solutions, Inc.
|
Buy |
9.36% |
-5.58% |
2025-01-30 |
|
RGNX
REGENXBIO Inc.
|
Buy |
8.51% |
4.46% |
2025-02-03 |
The percentage of cash held in the portfolio is:
63.2%
New Assets Added
None
Assets Removed
| Asset |
Action |
Perf % |
| MD |
Sell
All
|
-0.14% |
Assets Rebalanced
None
2025-02-05 00:00:00
: Portfolio change date
| Asset |
Action |
Weight |
PnL |
Entry Date |
|
MD
Pediatrix Medical Group, Inc.
|
Buy |
9.71% |
-0.64% |
2025-01-16 |
|
ORGO
Organogenesis Holdings Inc.
|
Buy |
9.49% |
4.5% |
2025-01-17 |
|
AGEN
Agenus Inc.
|
Buy |
8.42% |
-8.62% |
2025-01-22 |
|
BLFS
BioLife Solutions, Inc.
|
Buy |
9.36% |
-6.96% |
2025-01-30 |
|
RGNX
REGENXBIO Inc.
|
Buy |
8.64% |
4.46% |
2025-02-03 |
The percentage of cash held in the portfolio is:
54.38%
New Assets Added
None
Assets Removed
| Asset |
Action |
Perf % |
| NUTX |
Sell
All
|
52.16% |
| ACRS |
Sell
All
|
0.4% |
Assets Rebalanced
None
2025-02-04 00:00:00
: Portfolio change date
| Asset |
Action |
Weight |
PnL |
Entry Date |
|
NUTX
Nutex Health Inc.
|
Buy |
15.15% |
53.16% |
2025-01-15 |
|
ACRS
Aclaris Therapeutics, Inc.
|
Buy |
9.49% |
-4% |
2025-01-15 |
|
MD
Pediatrix Medical Group, Inc.
|
Buy |
9.82% |
-0.57% |
2025-01-16 |
|
ORGO
Organogenesis Holdings Inc.
|
Buy |
9.4% |
2.4% |
2025-01-17 |
|
AGEN
Agenus Inc.
|
Buy |
8.53% |
-8.36% |
2025-01-22 |
|
BLFS
BioLife Solutions, Inc.
|
Buy |
9.56% |
-5.94% |
2025-01-30 |
|
RGNX
REGENXBIO Inc.
|
Buy |
8.1% |
-3.1% |
2025-02-03 |
The percentage of cash held in the portfolio is:
29.96%
New Assets Added
None
Assets Removed
| Asset |
Action |
Perf % |
| AXGN |
Sell
All
|
-1.81% |
| INSM |
Sell
All
|
12.98% |
| SIGA |
Sell
All
|
-9.55% |
Assets Rebalanced
None
2025-02-03 00:00:00
: Portfolio change date
| Asset |
Action |
Weight |
PnL |
Entry Date |
|
AXGN
AxoGen, Inc.
|
Buy |
9.65% |
-0.22% |
2025-01-14 |
|
INSM
Insmed Incorporated
|
Buy |
10.74% |
11.1% |
2025-01-14 |
|
NUTX
Nutex Health Inc.
|
Buy |
14.42% |
48.84% |
2025-01-15 |
|
ACRS
Aclaris Therapeutics, Inc.
|
Buy |
9.61% |
-0.8% |
2025-01-15 |
|
MD
Pediatrix Medical Group, Inc.
|
Buy |
9.66% |
-0.14% |
2025-01-16 |
|
ORGO
Organogenesis Holdings Inc.
|
Buy |
9.93% |
10.51% |
2025-01-17 |
|
AGEN
Agenus Inc.
|
Buy |
9.04% |
-0.78% |
2025-01-22 |
|
SIGA
SIGA Technologies, Inc.
|
Buy |
7.16% |
-6.42% |
2025-01-23 |
|
BLFS
BioLife Solutions, Inc.
|
Buy |
9.61% |
-3.5% |
2025-01-30 |
|
RGNX
REGENXBIO Inc.
|
Buy |
8.18% |
0% |
2025-02-03 |
The percentage of cash held in the portfolio is:
2%
New Assets Added
Assets Removed
| Asset |
Action |
Perf % |
| TGTX |
Sell
All
|
-0.69% |
Assets Rebalanced
None
2025-01-30 00:00:00
: Portfolio change date
| Asset |
Action |
Weight |
PnL |
Entry Date |
|
AXGN
AxoGen, Inc.
|
Buy |
9.7% |
0.33% |
2025-01-14 |
|
INSM
Insmed Incorporated
|
Buy |
10.94% |
13.16% |
2025-01-14 |
|
NUTX
Nutex Health Inc.
|
Buy |
13.55% |
39.94% |
2025-01-15 |
|
ACRS
Aclaris Therapeutics, Inc.
|
Buy |
9.14% |
-5.6% |
2025-01-15 |
|
MD
Pediatrix Medical Group, Inc.
|
Buy |
9.8% |
1.36% |
2025-01-16 |
|
ORGO
Organogenesis Holdings Inc.
|
Buy |
10.25% |
14.11% |
2025-01-17 |
|
AGEN
Agenus Inc.
|
Buy |
8.59% |
-5.74% |
2025-01-22 |
|
SIGA
SIGA Technologies, Inc.
|
Buy |
7.49% |
-2.03% |
2025-01-23 |
|
TGTX
TG Therapeutics, Inc.
|
Buy |
8.61% |
4.54% |
2025-01-28 |
|
BLFS
BioLife Solutions, Inc.
|
Buy |
9.95% |
0% |
2025-01-30 |
The percentage of cash held in the portfolio is:
2%
New Assets Added
Assets Removed
| Asset |
Action |
Perf % |
| AORT |
Sell
All
|
3.27% |
Assets Rebalanced
None
2025-01-28 00:00:00
: Portfolio change date
| Asset |
Action |
Weight |
PnL |
Entry Date |
|
AORT
Artivion, Inc.
|
Buy |
9.95% |
1.36% |
2025-01-09 |
|
AXGN
AxoGen, Inc.
|
Buy |
9.64% |
-1.75% |
2025-01-14 |
|
INSM
Insmed Incorporated
|
Buy |
11.05% |
12.62% |
2025-01-14 |
|
NUTX
Nutex Health Inc.
|
Buy |
12.43% |
26.44% |
2025-01-15 |
|
ACRS
Aclaris Therapeutics, Inc.
|
Buy |
9.63% |
-2% |
2025-01-15 |
|
MD
Pediatrix Medical Group, Inc.
|
Buy |
10.29% |
4.86% |
2025-01-16 |
|
ORGO
Organogenesis Holdings Inc.
|
Buy |
10.24% |
12.31% |
2025-01-17 |
|
AGEN
Agenus Inc.
|
Buy |
8.69% |
-6.01% |
2025-01-22 |
|
SIGA
SIGA Technologies, Inc.
|
Buy |
7.71% |
-0.78% |
2025-01-23 |
|
TGTX
TG Therapeutics, Inc.
|
Buy |
8.36% |
0% |
2025-01-28 |
The percentage of cash held in the portfolio is:
2%
New Assets Added
Assets Removed
| Asset |
Action |
Perf % |
| ESPR |
Sell
All
|
-14.96% |
Assets Rebalanced
None
2025-01-23 00:00:00
: Portfolio change date
| Asset |
Action |
Weight |
PnL |
Entry Date |
|
AORT
Artivion, Inc.
|
Buy |
9.94% |
1.82% |
2025-01-09 |
|
ESPR
Esperion Therapeutics, Inc.
|
Buy |
9.18% |
-5.98% |
2025-01-13 |
|
AXGN
AxoGen, Inc.
|
Buy |
10.1% |
3.51% |
2025-01-14 |
|
INSM
Insmed Incorporated
|
Buy |
11.11% |
13.81% |
2025-01-14 |
|
NUTX
Nutex Health Inc.
|
Buy |
11.64% |
19.09% |
2025-01-15 |
|
ACRS
Aclaris Therapeutics, Inc.
|
Buy |
10.17% |
4% |
2025-01-15 |
|
MD
Pediatrix Medical Group, Inc.
|
Buy |
9.81% |
0.5% |
2025-01-16 |
|
ORGO
Organogenesis Holdings Inc.
|
Buy |
9.53% |
5.11% |
2025-01-17 |
|
AGEN
Agenus Inc.
|
Buy |
8.79% |
-4.44% |
2025-01-22 |
|
SIGA
SIGA Technologies, Inc.
|
Buy |
7.73% |
0% |
2025-01-23 |
The percentage of cash held in the portfolio is:
2%
New Assets Added
Assets Removed
| Asset |
Action |
Perf % |
| BLUE |
Sell
All
|
-20.97% |
Assets Rebalanced
None
2025-01-22 00:00:00
: Portfolio change date
| Asset |
Action |
Weight |
PnL |
Entry Date |
|
BLUE
bluebird bio, Inc.
|
Buy |
7.95% |
-17.94% |
2025-01-07 |
|
AORT
Artivion, Inc.
|
Buy |
10.13% |
4.5% |
2025-01-09 |
|
ESPR
Esperion Therapeutics, Inc.
|
Buy |
8.91% |
-8.12% |
2025-01-13 |
|
AXGN
AxoGen, Inc.
|
Buy |
10.07% |
3.95% |
2025-01-14 |
|
INSM
Insmed Incorporated
|
Buy |
10.79% |
11.34% |
2025-01-14 |
|
NUTX
Nutex Health Inc.
|
Buy |
11.68% |
20.31% |
2025-01-15 |
|
ACRS
Aclaris Therapeutics, Inc.
|
Buy |
10.09% |
4% |
2025-01-15 |
|
MD
Pediatrix Medical Group, Inc.
|
Buy |
9.69% |
0% |
2025-01-16 |
|
ORGO
Organogenesis Holdings Inc.
|
Buy |
9.55% |
6.01% |
2025-01-17 |
|
AGEN
Agenus Inc.
|
Buy |
9.13% |
0% |
2025-01-22 |
The percentage of cash held in the portfolio is:
2%
New Assets Added
Assets Removed
| Asset |
Action |
Perf % |
| TNDM |
Sell
All
|
-5.5% |
Assets Rebalanced
None
2025-01-17 00:00:00
: Portfolio change date
| Asset |
Action |
Weight |
PnL |
Entry Date |
|
TNDM
Tandem Diabetes Care, Inc.
|
Buy |
9.84% |
0.47% |
2025-01-07 |
|
BLUE
bluebird bio, Inc.
|
Buy |
8.15% |
-16.73% |
2025-01-07 |
|
AORT
Artivion, Inc.
|
Buy |
10.12% |
3.34% |
2025-01-09 |
|
ESPR
Esperion Therapeutics, Inc.
|
Buy |
9.46% |
-3.42% |
2025-01-13 |
|
AXGN
AxoGen, Inc.
|
Buy |
9.89% |
0.99% |
2025-01-14 |
|
INSM
Insmed Incorporated
|
Buy |
10.34% |
5.54% |
2025-01-14 |
|
NUTX
Nutex Health Inc.
|
Buy |
11.61% |
18.31% |
2025-01-15 |
|
ACRS
Aclaris Therapeutics, Inc.
|
Buy |
9.85% |
0.4% |
2025-01-15 |
|
MD
Pediatrix Medical Group, Inc.
|
Buy |
9.64% |
-1.64% |
2025-01-16 |
|
ORGO
Organogenesis Holdings Inc.
|
Buy |
9.1% |
0% |
2025-01-17 |
The percentage of cash held in the portfolio is:
2%
New Assets Added
Assets Removed
| Asset |
Action |
Perf % |
| MDRX |
Sell
All
|
-6.56% |
Assets Rebalanced
None
2025-01-16 00:00:00
: Portfolio change date
| Asset |
Action |
Weight |
PnL |
Entry Date |
|
TNDM
Tandem Diabetes Care, Inc.
|
Buy |
9.65% |
-3.76% |
2025-01-07 |
|
BLUE
bluebird bio, Inc.
|
Buy |
8.38% |
-16.43% |
2025-01-07 |
|
MDRX
Allscripts Healthcare Solutions, Inc.
|
Buy |
9.58% |
-4.51% |
2025-01-08 |
|
AORT
Artivion, Inc.
|
Buy |
9.98% |
-0.56% |
2025-01-09 |
|
ESPR
Esperion Therapeutics, Inc.
|
Buy |
9.48% |
-5.56% |
2025-01-13 |
|
AXGN
AxoGen, Inc.
|
Buy |
10.3% |
2.63% |
2025-01-14 |
|
INSM
Insmed Incorporated
|
Buy |
10.22% |
1.84% |
2025-01-14 |
|
NUTX
Nutex Health Inc.
|
Buy |
10.27% |
2.16% |
2025-01-15 |
|
ACRS
Aclaris Therapeutics, Inc.
|
Buy |
10.09% |
0.4% |
2025-01-15 |
|
MD
Pediatrix Medical Group, Inc.
|
Buy |
10.04% |
0% |
2025-01-16 |
The percentage of cash held in the portfolio is:
2%
New Assets Added
Assets Removed
| Asset |
Action |
Perf % |
| ARDX |
Sell
All
|
0.19% |
Assets Rebalanced
None
2025-01-15 00:00:00
: Portfolio change date
| Asset |
Action |
Weight |
PnL |
Entry Date |
|
TNDM
Tandem Diabetes Care, Inc.
|
Buy |
9.69% |
-4.19% |
2025-01-07 |
|
BLUE
bluebird bio, Inc.
|
Buy |
8.17% |
-19.25% |
2025-01-07 |
|
MDRX
Allscripts Healthcare Solutions, Inc.
|
Buy |
9.44% |
-6.67% |
2025-01-08 |
|
AORT
Artivion, Inc.
|
Buy |
9.94% |
-1.82% |
2025-01-09 |
|
ARDX
Ardelyx, Inc.
|
Buy |
10.65% |
5.24% |
2025-01-09 |
|
ESPR
Esperion Therapeutics, Inc.
|
Buy |
9.69% |
-4.27% |
2025-01-13 |
|
AXGN
AxoGen, Inc.
|
Buy |
10.11% |
-0.05% |
2025-01-14 |
|
INSM
Insmed Incorporated
|
Buy |
10.03% |
-0.93% |
2025-01-14 |
|
NUTX
Nutex Health Inc.
|
Buy |
10.14% |
0% |
2025-01-15 |
|
ACRS
Aclaris Therapeutics, Inc.
|
Buy |
10.14% |
0% |
2025-01-15 |
The percentage of cash held in the portfolio is:
2%
New Assets Added
Assets Removed
None
Assets Rebalanced
None
2025-01-14 00:00:00
: Portfolio change date
| Asset |
Action |
Weight |
PnL |
Entry Date |
|
TNDM
Tandem Diabetes Care, Inc.
|
Buy |
9.65% |
-3.07% |
2025-01-07 |
|
BLUE
bluebird bio, Inc.
|
Buy |
8.52% |
-14.42% |
2025-01-07 |
|
MDRX
Allscripts Healthcare Solutions, Inc.
|
Buy |
9.7% |
-2.56% |
2025-01-08 |
|
AORT
Artivion, Inc.
|
Buy |
9.66% |
-2.94% |
2025-01-09 |
|
ARDX
Ardelyx, Inc.
|
Buy |
10.96% |
10.11% |
2025-01-09 |
|
ESPR
Esperion Therapeutics, Inc.
|
Buy |
9.7% |
-2.56% |
2025-01-13 |
|
AXGN
AxoGen, Inc.
|
Buy |
9.95% |
0% |
2025-01-14 |
|
INSM
Insmed Incorporated
|
Buy |
9.95% |
0% |
2025-01-14 |
The percentage of cash held in the portfolio is:
21.91%
New Assets Added
Assets Removed
None
Assets Rebalanced
None
2025-01-13 00:00:00
: Portfolio change date
| Asset |
Action |
Weight |
PnL |
Entry Date |
|
TNDM
Tandem Diabetes Care, Inc.
|
Buy |
9.7% |
-3.63% |
2025-01-07 |
|
BLUE
bluebird bio, Inc.
|
Buy |
8.59% |
-14.72% |
2025-01-07 |
|
MDRX
Allscripts Healthcare Solutions, Inc.
|
Buy |
9.82% |
-2.46% |
2025-01-08 |
|
AORT
Artivion, Inc.
|
Buy |
9.95% |
-1.16% |
2025-01-09 |
|
ARDX
Ardelyx, Inc.
|
Buy |
9.56% |
-5.06% |
2025-01-09 |
|
ESPR
Esperion Therapeutics, Inc.
|
Buy |
10.08% |
0% |
2025-01-13 |
The percentage of cash held in the portfolio is:
42.3%
New Assets Added
Assets Removed
None
Assets Rebalanced
None
2025-01-09 00:00:00
: Portfolio change date
| Asset |
Action |
Weight |
PnL |
Entry Date |
|
TNDM
Tandem Diabetes Care, Inc.
|
Buy |
10% |
0.36% |
2025-01-07 |
|
BLUE
bluebird bio, Inc.
|
Buy |
8.5% |
-14.72% |
2025-01-07 |
|
MDRX
Allscripts Healthcare Solutions, Inc.
|
Buy |
9.72% |
-2.46% |
2025-01-08 |
|
AORT
Artivion, Inc.
|
Buy |
9.97% |
0% |
2025-01-09 |
|
ARDX
Ardelyx, Inc.
|
Buy |
9.97% |
0% |
2025-01-09 |
The percentage of cash held in the portfolio is:
51.84%
New Assets Added
Assets Removed
None
Assets Rebalanced
None
2025-01-08 00:00:00
: Portfolio change date
| Asset |
Action |
Weight |
PnL |
Entry Date |
|
TNDM
Tandem Diabetes Care, Inc.
|
Buy |
9.82% |
-0.82% |
2025-01-07 |
|
BLUE
bluebird bio, Inc.
|
Buy |
9% |
-9.07% |
2025-01-07 |
|
MDRX
Allscripts Healthcare Solutions, Inc.
|
Buy |
9.9% |
0% |
2025-01-08 |
The percentage of cash held in the portfolio is:
71.29%
New Assets Added
Assets Removed
None
Assets Rebalanced
None
2025-01-07 00:00:00
: Portfolio change date
| Asset |
Action |
Weight |
PnL |
Entry Date |
|
TNDM
Tandem Diabetes Care, Inc.
|
Buy |
9.8% |
0% |
2025-01-07 |
|
BLUE
bluebird bio, Inc.
|
Buy |
9.8% |
0% |
2025-01-07 |
The percentage of cash held in the portfolio is:
80.4%
New Assets Added
Assets Removed
None
Assets Rebalanced
None
2024-12-26 00:00:00
: Portfolio change date
No Asset in the portfolio
The percentage of cash held in the portfolio is:
100%
New Assets Added
None
Assets Removed
| Asset |
Action |
Perf % |
| PCRX |
Sell
All
|
NA |
Assets Rebalanced
None
2024-12-18 00:00:00
: Portfolio change date
| Asset |
Action |
Weight |
PnL |
Entry Date |
|
PCRX
Pacira BioSciences, Inc.
|
Buy |
10.44% |
3.88% |
2024-12-05 |
The percentage of cash held in the portfolio is:
89.56%
New Assets Added
None
Assets Removed
| Asset |
Action |
Perf % |
| APLS |
Sell
All
|
5.82% |
| MGNX |
Sell
All
|
-1.76% |
Assets Rebalanced
None
2024-12-12 00:00:00
: Portfolio change date
| Asset |
Action |
Weight |
PnL |
Entry Date |
|
APLS
Apellis Pharmaceuticals, Inc.
|
Buy |
10.71% |
4.2% |
2024-11-27 |
|
MGNX
MacroGenics, Inc.
|
Buy |
10.31% |
0.29% |
2024-11-27 |
|
PCRX
Pacira BioSciences, Inc.
|
Buy |
10.67% |
6.5% |
2024-12-05 |
The percentage of cash held in the portfolio is:
68.32%
New Assets Added
None
Assets Removed
| Asset |
Action |
Perf % |
| ESPR |
Sell
All
|
-13.23% |
Assets Rebalanced
None
2024-12-10 00:00:00
: Portfolio change date
| Asset |
Action |
Weight |
PnL |
Entry Date |
|
APLS
Apellis Pharmaceuticals, Inc.
|
Buy |
10.64% |
7.32% |
2024-11-27 |
|
MGNX
MacroGenics, Inc.
|
Buy |
10.15% |
2.35% |
2024-11-27 |
|
ESPR
Esperion Therapeutics, Inc.
|
Buy |
12.13% |
23.55% |
2024-12-03 |
|
PCRX
Pacira BioSciences, Inc.
|
Buy |
9.67% |
0% |
2024-12-05 |
The percentage of cash held in the portfolio is:
57.41%
New Assets Added
None
Assets Removed
| Asset |
Action |
Perf % |
| RVNC |
Sell
All
|
-27.34% |
Assets Rebalanced
None
2024-12-05 00:00:00
: Portfolio change date
| Asset |
Action |
Weight |
PnL |
Entry Date |
|
APLS
Apellis Pharmaceuticals, Inc.
|
Buy |
10.18% |
4.6% |
2024-11-27 |
|
MGNX
MacroGenics, Inc.
|
Buy |
9.99% |
2.65% |
2024-11-27 |
|
ESPR
Esperion Therapeutics, Inc.
|
Buy |
11.38% |
18.06% |
2024-12-03 |
|
RVNC
Revance Therapeutics, Inc.
|
Buy |
9.49% |
0% |
2024-12-05 |
|
PCRX
Pacira BioSciences, Inc.
|
Buy |
9.49% |
0% |
2024-12-05 |
The percentage of cash held in the portfolio is:
49.46%
New Assets Added
Assets Removed
| Asset |
Action |
Perf % |
| ARWR |
Sell
All
|
-11.63% |
Assets Rebalanced
None
2024-12-03 00:00:00
: Portfolio change date
| Asset |
Action |
Weight |
PnL |
Entry Date |
|
APLS
Apellis Pharmaceuticals, Inc.
|
Buy |
10.52% |
8.55% |
2024-11-27 |
|
MGNX
MacroGenics, Inc.
|
Buy |
10.52% |
8.53% |
2024-11-27 |
|
ARWR
Arrowhead Pharmaceuticals, Inc.
|
Buy |
9.76% |
0.73% |
2024-11-28 |
|
ESPR
Esperion Therapeutics, Inc.
|
Buy |
9.6% |
0% |
2024-12-03 |
The percentage of cash held in the portfolio is:
59.6%
New Assets Added
Assets Removed
| Asset |
Action |
Perf % |
| FATE |
Sell
All
|
-6.62% |
Assets Rebalanced
None
2024-11-28 00:00:00
: Portfolio change date
| Asset |
Action |
Weight |
PnL |
Entry Date |
|
APLS
Apellis Pharmaceuticals, Inc.
|
Buy |
10.14% |
4.63% |
2024-11-27 |
|
MGNX
MacroGenics, Inc.
|
Buy |
10.37% |
7.06% |
2024-11-27 |
|
ARWR
Arrowhead Pharmaceuticals, Inc.
|
Buy |
9.69% |
0% |
2024-11-28 |
|
FATE
Fate Therapeutics, Inc.
|
Buy |
9.69% |
0% |
2024-11-28 |
The percentage of cash held in the portfolio is:
60.12%
New Assets Added
Assets Removed
None
Assets Rebalanced
None
2024-11-27 00:00:00
: Portfolio change date
| Asset |
Action |
Weight |
PnL |
Entry Date |
|
APLS
Apellis Pharmaceuticals, Inc.
|
Buy |
9.8% |
0% |
2024-11-27 |
|
MGNX
MacroGenics, Inc.
|
Buy |
9.8% |
0% |
2024-11-27 |
The percentage of cash held in the portfolio is:
80.4%
New Assets Added
Assets Removed
None
Assets Rebalanced
None
2024-11-26 00:00:00
: Portfolio change date
No Asset in the portfolio
The percentage of cash held in the portfolio is:
100%
New Assets Added
None
Assets Removed
| Asset |
Action |
Perf % |
| CORT |
Sell
All
|
17.92% |
Assets Rebalanced
None
2024-11-21 00:00:00
: Portfolio change date
| Asset |
Action |
Weight |
PnL |
Entry Date |
|
CORT
Corcept Therapeutics Incorporated
|
Buy |
10.51% |
12.05% |
2024-11-05 |
The percentage of cash held in the portfolio is:
89.49%
New Assets Added
None
Assets Removed
| Asset |
Action |
Perf % |
| IRTC |
Sell
All
|
-9.45% |
Assets Rebalanced
None
2024-11-20 00:00:00
: Portfolio change date
| Asset |
Action |
Weight |
PnL |
Entry Date |
|
IRTC
iRhythm Technologies, Inc.
|
Buy |
8.7% |
-7.33% |
2024-11-05 |
|
CORT
Corcept Therapeutics Incorporated
|
Buy |
10.19% |
8.49% |
2024-11-05 |
The percentage of cash held in the portfolio is:
81.11%
New Assets Added
None
Assets Removed
| Asset |
Action |
Perf % |
| NEOG |
Sell
All
|
5.23% |
| MGNX |
Sell
All
|
-10.08% |
Assets Rebalanced
None
2024-11-19 00:00:00
: Portfolio change date
| Asset |
Action |
Weight |
PnL |
Entry Date |
|
NEOG
Neogen Corporation
|
Buy |
8.24% |
6% |
2024-10-30 |
|
MGNX
MacroGenics, Inc.
|
Buy |
8.22% |
-9.3% |
2024-11-04 |
|
IRTC
iRhythm Technologies, Inc.
|
Buy |
8.86% |
-5.62% |
2024-11-05 |
|
CORT
Corcept Therapeutics Incorporated
|
Buy |
9.87% |
5.11% |
2024-11-05 |
The percentage of cash held in the portfolio is:
64.81%
New Assets Added
None
Assets Removed
| Asset |
Action |
Perf % |
| HCSG |
Sell
All
|
2.56% |
Assets Rebalanced
None
2024-11-18 00:00:00
: Portfolio change date
| Asset |
Action |
Weight |
PnL |
Entry Date |
|
HCSG
Healthcare Services Group, Inc.
|
Buy |
14.17% |
5.39% |
2024-10-29 |
|
NEOG
Neogen Corporation
|
Buy |
7.88% |
1.81% |
2024-10-30 |
|
MGNX
MacroGenics, Inc.
|
Buy |
8.32% |
-7.75% |
2024-11-04 |
|
IRTC
iRhythm Technologies, Inc.
|
Buy |
9.23% |
-1.22% |
2024-11-05 |
|
CORT
Corcept Therapeutics Incorporated
|
Buy |
9.68% |
3.54% |
2024-11-05 |
The percentage of cash held in the portfolio is:
50.72%
New Assets Added
None
Assets Removed
| Asset |
Action |
Perf % |
| RGEN |
Sell
All
|
-17.11% |
Assets Rebalanced
None
2024-11-15 00:00:00
: Portfolio change date
| Asset |
Action |
Weight |
PnL |
Entry Date |
|
HCSG
Healthcare Services Group, Inc.
|
Buy |
14.2% |
8.95% |
2024-10-29 |
|
NEOG
Neogen Corporation
|
Buy |
7.65% |
2.09% |
2024-10-30 |
|
MGNX
MacroGenics, Inc.
|
Buy |
8.61% |
-1.55% |
2024-11-04 |
|
IRTC
iRhythm Technologies, Inc.
|
Buy |
9.28% |
2.46% |
2024-11-05 |
|
CORT
Corcept Therapeutics Incorporated
|
Buy |
9.92% |
9.45% |
2024-11-05 |
|
RGEN
Repligen Corporation
|
Buy |
9.53% |
-5.34% |
2024-11-14 |
The percentage of cash held in the portfolio is:
40.81%
New Assets Added
None
Assets Removed
| Asset |
Action |
Perf % |
| SAGE |
Sell
All
|
-15.03% |
| ALT |
Sell
All
|
-10.91% |
Assets Rebalanced
None
2024-11-14 00:00:00
: Portfolio change date
| Asset |
Action |
Weight |
PnL |
Entry Date |
|
HCSG
Healthcare Services Group, Inc.
|
Buy |
13.99% |
11.32% |
2024-10-29 |
|
NEOG
Neogen Corporation
|
Buy |
7.66% |
5.86% |
2024-10-30 |
|
MGNX
MacroGenics, Inc.
|
Buy |
8.22% |
-2.58% |
2024-11-04 |
|
IRTC
iRhythm Technologies, Inc.
|
Buy |
9.35% |
6.99% |
2024-11-05 |
|
CORT
Corcept Therapeutics Incorporated
|
Buy |
9.86% |
12.76% |
2024-11-05 |
|
SAGE
Sage Therapeutics, Inc.
|
Buy |
7.67% |
-9.34% |
2024-11-08 |
|
ALT
Altimmune, Inc.
|
Buy |
12.12% |
0.32% |
2024-11-13 |
|
RGEN
Repligen Corporation
|
Buy |
9.71% |
0% |
2024-11-14 |
The percentage of cash held in the portfolio is:
21.42%
New Assets Added
Assets Removed
| Asset |
Action |
Perf % |
| CARA |
Sell
All
|
-6.09% |
| CDMO |
Sell
All
|
17.76% |
Assets Rebalanced
None
2024-11-13 00:00:00
: Portfolio change date
| Asset |
Action |
Weight |
PnL |
Entry Date |
|
CDMO
Avid Bioservices, Inc.
|
Buy |
8.94% |
18.05% |
2024-10-24 |
|
HCSG
Healthcare Services Group, Inc.
|
Buy |
14.04% |
13.61% |
2024-10-29 |
|
NEOG
Neogen Corporation
|
Buy |
7.61% |
6.97% |
2024-10-30 |
|
MGNX
MacroGenics, Inc.
|
Buy |
8.79% |
5.94% |
2024-11-04 |
|
IRTC
iRhythm Technologies, Inc.
|
Buy |
9.2% |
7.07% |
2024-11-05 |
|
CORT
Corcept Therapeutics Incorporated
|
Buy |
9.92% |
15.44% |
2024-11-05 |
|
CARA
Cara Therapeutics, Inc.
|
Buy |
8.22% |
-1.16% |
2024-11-08 |
|
SAGE
Sage Therapeutics, Inc.
|
Buy |
7.54% |
-9.34% |
2024-11-08 |
|
ALT
Altimmune, Inc.
|
Buy |
11.87% |
0% |
2024-11-13 |
The percentage of cash held in the portfolio is:
13.87%
New Assets Added
Assets Removed
| Asset |
Action |
Perf % |
| IOVA |
Sell
All
|
-12.15% |
| NUTX |
Sell
All
|
51.33% |
Assets Rebalanced
None
2024-11-08 00:00:00
: Portfolio change date
| Asset |
Action |
Weight |
PnL |
Entry Date |
|
NUTX
Nutex Health Inc.
|
Buy |
9.85% |
16.4% |
2024-10-23 |
|
CDMO
Avid Bioservices, Inc.
|
Buy |
8.9% |
18.15% |
2024-10-24 |
|
HCSG
Healthcare Services Group, Inc.
|
Buy |
13.18% |
7.31% |
2024-10-29 |
|
IOVA
Iovance Biotherapeutics, Inc.
|
Buy |
13.68% |
11.33% |
2024-10-29 |
|
NEOG
Neogen Corporation
|
Buy |
7.78% |
10.04% |
2024-10-30 |
|
MGNX
MacroGenics, Inc.
|
Buy |
9.5% |
15.25% |
2024-11-04 |
|
IRTC
iRhythm Technologies, Inc.
|
Buy |
9.31% |
8.99% |
2024-11-05 |
|
CORT
Corcept Therapeutics Incorporated
|
Buy |
9.27% |
8.47% |
2024-11-05 |
|
CARA
Cara Therapeutics, Inc.
|
Buy |
8.27% |
0% |
2024-11-08 |
|
SAGE
Sage Therapeutics, Inc.
|
Buy |
8.27% |
0% |
2024-11-08 |
The percentage of cash held in the portfolio is:
2%
New Assets Added
Assets Removed
| Asset |
Action |
Perf % |
| NVRO |
Sell
All
|
-1.11% |
| VREX |
Sell
All
|
17.93% |
Assets Rebalanced
None
2024-11-05 00:00:00
: Portfolio change date
| Asset |
Action |
Weight |
PnL |
Entry Date |
|
VREX
Varex Imaging Corporation
|
Buy |
9.72% |
9.5% |
2024-10-18 |
|
NUTX
Nutex Health Inc.
|
Buy |
8.67% |
-7.17% |
2024-10-23 |
|
CDMO
Avid Bioservices, Inc.
|
Buy |
8.29% |
-0.19% |
2024-10-24 |
|
HCSG
Healthcare Services Group, Inc.
|
Buy |
13.83% |
2.01% |
2024-10-29 |
|
IOVA
Iovance Biotherapeutics, Inc.
|
Buy |
14.06% |
3.72% |
2024-10-29 |
|
NEOG
Neogen Corporation
|
Buy |
7.85% |
0.63% |
2024-10-30 |
|
NVRO
Nevro Corp.
|
Buy |
8.01% |
-0.93% |
2024-10-31 |
|
MGNX
MacroGenics, Inc.
|
Buy |
8.7% |
-4.39% |
2024-11-04 |
|
IRTC
iRhythm Technologies, Inc.
|
Buy |
9.43% |
0% |
2024-11-05 |
|
CORT
Corcept Therapeutics Incorporated
|
Buy |
9.43% |
0% |
2024-11-05 |
The percentage of cash held in the portfolio is:
2%
New Assets Added
Assets Removed
| Asset |
Action |
Perf % |
| ARWR |
Sell
All
|
3.62% |
| VCEL |
Sell
All
|
5.42% |
Assets Rebalanced
None
2024-11-04 00:00:00
: Portfolio change date
| Asset |
Action |
Weight |
PnL |
Entry Date |
|
ARWR
Arrowhead Pharmaceuticals, Inc.
|
Buy |
9.11% |
0.67% |
2024-10-15 |
|
VCEL
Vericel Corporation
|
Buy |
9.46% |
4.51% |
2024-10-15 |
|
VREX
Varex Imaging Corporation
|
Buy |
9.71% |
9.09% |
2024-10-18 |
|
NUTX
Nutex Health Inc.
|
Buy |
8.53% |
-8.94% |
2024-10-23 |
|
CDMO
Avid Bioservices, Inc.
|
Buy |
8.26% |
-0.87% |
2024-10-24 |
|
HCSG
Healthcare Services Group, Inc.
|
Buy |
13.84% |
1.83% |
2024-10-29 |
|
IOVA
Iovance Biotherapeutics, Inc.
|
Buy |
13.79% |
1.45% |
2024-10-29 |
|
NEOG
Neogen Corporation
|
Buy |
7.88% |
0.7% |
2024-10-30 |
|
NVRO
Nevro Corp.
|
Buy |
8.3% |
2.41% |
2024-10-31 |
|
MGNX
MacroGenics, Inc.
|
Buy |
9.12% |
0% |
2024-11-04 |
The percentage of cash held in the portfolio is:
2%
New Assets Added
Assets Removed
| Asset |
Action |
Perf % |
| ARDX |
Sell
All
|
0.83% |
Assets Rebalanced
None
2024-10-31 00:00:00
: Portfolio change date
| Asset |
Action |
Weight |
PnL |
Entry Date |
|
ARDX
Ardelyx, Inc.
|
Buy |
8.82% |
-2.48% |
2024-10-14 |
|
ARWR
Arrowhead Pharmaceuticals, Inc.
|
Buy |
9.2% |
1.81% |
2024-10-15 |
|
VCEL
Vericel Corporation
|
Buy |
9.78% |
8.2% |
2024-10-15 |
|
VREX
Varex Imaging Corporation
|
Buy |
9.81% |
10.33% |
2024-10-18 |
|
NUTX
Nutex Health Inc.
|
Buy |
8.87% |
-5.16% |
2024-10-23 |
|
CDMO
Avid Bioservices, Inc.
|
Buy |
8.16% |
-2.03% |
2024-10-24 |
|
HCSG
Healthcare Services Group, Inc.
|
Buy |
13.71% |
0.91% |
2024-10-29 |
|
IOVA
Iovance Biotherapeutics, Inc.
|
Buy |
13.6% |
0.09% |
2024-10-29 |
|
NEOG
Neogen Corporation
|
Buy |
7.94% |
1.6% |
2024-10-30 |
|
NVRO
Nevro Corp.
|
Buy |
8.1% |
0% |
2024-10-31 |
The percentage of cash held in the portfolio is:
2%
New Assets Added
Assets Removed
| Asset |
Action |
Perf % |
| ALGN |
Sell
All
|
-2.57% |
Assets Rebalanced
None
2024-10-30 00:00:00
: Portfolio change date
| Asset |
Action |
Weight |
PnL |
Entry Date |
|
ARDX
Ardelyx, Inc.
|
Buy |
9.05% |
-0.5% |
2024-10-14 |
|
ARWR
Arrowhead Pharmaceuticals, Inc.
|
Buy |
9.38% |
3.2% |
2024-10-15 |
|
VCEL
Vericel Corporation
|
Buy |
9.9% |
8.89% |
2024-10-15 |
|
VREX
Varex Imaging Corporation
|
Buy |
9.84% |
10% |
2024-10-18 |
|
NUTX
Nutex Health Inc.
|
Buy |
8.38% |
-10.96% |
2024-10-23 |
|
CDMO
Avid Bioservices, Inc.
|
Buy |
8.23% |
-1.74% |
2024-10-24 |
|
ALGN
Align Technology, Inc.
|
Buy |
8.23% |
-1.68% |
2024-10-25 |
|
HCSG
Healthcare Services Group, Inc.
|
Buy |
13.75% |
0.64% |
2024-10-29 |
|
IOVA
Iovance Biotherapeutics, Inc.
|
Buy |
13.39% |
-1.99% |
2024-10-29 |
|
NEOG
Neogen Corporation
|
Buy |
7.86% |
0% |
2024-10-30 |
The percentage of cash held in the portfolio is:
2%
New Assets Added
Assets Removed
| Asset |
Action |
Perf % |
| NKTR |
Sell
All
|
-12.41% |
Assets Rebalanced
None
2024-10-29 00:00:00
: Portfolio change date
| Asset |
Action |
Weight |
PnL |
Entry Date |
|
ARDX
Ardelyx, Inc.
|
Buy |
8.77% |
-2.32% |
2024-10-14 |
|
ARWR
Arrowhead Pharmaceuticals, Inc.
|
Buy |
9.36% |
4.24% |
2024-10-15 |
|
VCEL
Vericel Corporation
|
Buy |
9.74% |
8.48% |
2024-10-15 |
|
VREX
Varex Imaging Corporation
|
Buy |
9.6% |
8.68% |
2024-10-18 |
|
NKTR
Nektar Therapeutics
|
Buy |
8.28% |
-6.21% |
2024-10-18 |
|
NUTX
Nutex Health Inc.
|
Buy |
8.98% |
-3.3% |
2024-10-23 |
|
CDMO
Avid Bioservices, Inc.
|
Buy |
8.06% |
-2.51% |
2024-10-24 |
|
ALGN
Align Technology, Inc.
|
Buy |
8.24% |
-0.29% |
2024-10-25 |
|
HCSG
Healthcare Services Group, Inc.
|
Buy |
13.49% |
0% |
2024-10-29 |
|
IOVA
Iovance Biotherapeutics, Inc.
|
Buy |
13.49% |
0% |
2024-10-29 |
The percentage of cash held in the portfolio is:
2%
New Assets Added
Assets Removed
| Asset |
Action |
Perf % |
| SGMO |
Sell
All
|
110.31% |
Assets Rebalanced
None
2024-10-28 00:00:00
: Portfolio change date
| Asset |
Action |
Weight |
PnL |
Entry Date |
|
ARDX
Ardelyx, Inc.
|
Buy |
9.11% |
-4.47% |
2024-10-14 |
|
ARWR
Arrowhead Pharmaceuticals, Inc.
|
Buy |
9.9% |
3.82% |
2024-10-15 |
|
VCEL
Vericel Corporation
|
Buy |
9.91% |
3.94% |
2024-10-15 |
|
SGMO
Sangamo Therapeutics, Inc.
|
Buy |
14.74% |
54.64% |
2024-10-16 |
|
VREX
Varex Imaging Corporation
|
Buy |
10.01% |
6.69% |
2024-10-18 |
|
NKTR
Nektar Therapeutics
|
Buy |
8.54% |
-8.97% |
2024-10-18 |
|
NUTX
Nutex Health Inc.
|
Buy |
9.66% |
-2.14% |
2024-10-23 |
|
CDMO
Avid Bioservices, Inc.
|
Buy |
8.48% |
-3.47% |
2024-10-24 |
|
ALGN
Align Technology, Inc.
|
Buy |
8.9% |
1.33% |
2024-10-25 |
The percentage of cash held in the portfolio is:
10.74%
New Assets Added
None
Assets Removed
| Asset |
Action |
Perf % |
| ORGO |
Sell
All
|
-9.09% |
Assets Rebalanced
None
2024-10-25 00:00:00
: Portfolio change date
| Asset |
Action |
Weight |
PnL |
Entry Date |
|
ORGO
Organogenesis Holdings Inc.
|
Buy |
8.93% |
-6.82% |
2024-10-07 |
|
ARDX
Ardelyx, Inc.
|
Buy |
9.23% |
-2.98% |
2024-10-14 |
|
ARWR
Arrowhead Pharmaceuticals, Inc.
|
Buy |
9.79% |
2.94% |
2024-10-15 |
|
VCEL
Vericel Corporation
|
Buy |
9.69% |
1.85% |
2024-10-15 |
|
SGMO
Sangamo Therapeutics, Inc.
|
Buy |
14.6% |
53.61% |
2024-10-16 |
|
VREX
Varex Imaging Corporation
|
Buy |
9.91% |
5.95% |
2024-10-18 |
|
NKTR
Nektar Therapeutics
|
Buy |
8.71% |
-6.9% |
2024-10-18 |
|
NUTX
Nutex Health Inc.
|
Buy |
9.75% |
-0.97% |
2024-10-23 |
|
CDMO
Avid Bioservices, Inc.
|
Buy |
8.63% |
-1.45% |
2024-10-24 |
|
ALGN
Align Technology, Inc.
|
Buy |
8.76% |
0% |
2024-10-25 |
The percentage of cash held in the portfolio is:
2%
New Assets Added
Assets Removed
None
Assets Rebalanced
None
2024-10-24 00:00:00
: Portfolio change date
| Asset |
Action |
Weight |
PnL |
Entry Date |
|
ORGO
Organogenesis Holdings Inc.
|
Buy |
8.99% |
-6.17% |
2024-10-07 |
|
ARDX
Ardelyx, Inc.
|
Buy |
8.78% |
-7.62% |
2024-10-14 |
|
ARWR
Arrowhead Pharmaceuticals, Inc.
|
Buy |
9.78% |
2.89% |
2024-10-15 |
|
VCEL
Vericel Corporation
|
Buy |
9.55% |
0.45% |
2024-10-15 |
|
SGMO
Sangamo Therapeutics, Inc.
|
Buy |
15.08% |
58.76% |
2024-10-16 |
|
VREX
Varex Imaging Corporation
|
Buy |
9.86% |
5.37% |
2024-10-18 |
|
NKTR
Nektar Therapeutics
|
Buy |
9.09% |
-2.76% |
2024-10-18 |
|
NUTX
Nutex Health Inc.
|
Buy |
9.36% |
-4.88% |
2024-10-23 |
|
CDMO
Avid Bioservices, Inc.
|
Buy |
8.75% |
0% |
2024-10-24 |
The percentage of cash held in the portfolio is:
10.75%
New Assets Added
Assets Removed
| Asset |
Action |
Perf % |
| IRWD |
Sell
All
|
-6.57% |
| CDXS |
Sell
All
|
-9.73% |
Assets Rebalanced
None
2024-10-23 00:00:00
: Portfolio change date
| Asset |
Action |
Weight |
PnL |
Entry Date |
|
IRWD
Ironwood Pharmaceuticals, Inc.
|
Buy |
9.24% |
-4.23% |
2024-10-03 |
|
ORGO
Organogenesis Holdings Inc.
|
Buy |
9.71% |
0.65% |
2024-10-07 |
|
ARDX
Ardelyx, Inc.
|
Buy |
9.16% |
-4.3% |
2024-10-14 |
|
ARWR
Arrowhead Pharmaceuticals, Inc.
|
Buy |
10.08% |
5.27% |
2024-10-15 |
|
VCEL
Vericel Corporation
|
Buy |
9.52% |
-0.62% |
2024-10-15 |
|
CDXS
Codexis, Inc.
|
Buy |
9.32% |
-2.65% |
2024-10-16 |
|
SGMO
Sangamo Therapeutics, Inc.
|
Buy |
11.94% |
24.74% |
2024-10-16 |
|
VREX
Varex Imaging Corporation
|
Buy |
9.76% |
3.64% |
2024-10-18 |
|
NKTR
Nektar Therapeutics
|
Buy |
9.36% |
-0.69% |
2024-10-18 |
|
NUTX
Nutex Health Inc.
|
Buy |
9.91% |
0% |
2024-10-23 |
The percentage of cash held in the portfolio is:
2%
New Assets Added
Assets Removed
None
Assets Rebalanced
None
2024-10-22 00:00:00
: Portfolio change date
| Asset |
Action |
Weight |
PnL |
Entry Date |
|
IRWD
Ironwood Pharmaceuticals, Inc.
|
Buy |
9.77% |
-1.64% |
2024-10-03 |
|
ORGO
Organogenesis Holdings Inc.
|
Buy |
10.03% |
0.97% |
2024-10-07 |
|
ARDX
Ardelyx, Inc.
|
Buy |
9.6% |
-2.65% |
2024-10-14 |
|
ARWR
Arrowhead Pharmaceuticals, Inc.
|
Buy |
10.44% |
5.84% |
2024-10-15 |
|
VCEL
Vericel Corporation
|
Buy |
9.65% |
-2.16% |
2024-10-15 |
|
CDXS
Codexis, Inc.
|
Buy |
9.57% |
-2.95% |
2024-10-16 |
|
SGMO
Sangamo Therapeutics, Inc.
|
Buy |
9.25% |
-6.19% |
2024-10-16 |
|
VREX
Varex Imaging Corporation
|
Buy |
10.11% |
4.13% |
2024-10-18 |
|
NKTR
Nektar Therapeutics
|
Buy |
9.3% |
-4.14% |
2024-10-18 |
The percentage of cash held in the portfolio is:
12.27%
New Assets Added
None
Assets Removed
| Asset |
Action |
Perf % |
| BKD |
Sell
All
|
3.8% |
Assets Rebalanced
None
2024-10-18 00:00:00
: Portfolio change date
| Asset |
Action |
Weight |
PnL |
Entry Date |
|
IRWD
Ironwood Pharmaceuticals, Inc.
|
Buy |
10.2% |
4.23% |
2024-10-03 |
|
ORGO
Organogenesis Holdings Inc.
|
Buy |
9.76% |
-0.32% |
2024-10-07 |
|
ARDX
Ardelyx, Inc.
|
Buy |
9.38% |
-3.48% |
2024-10-14 |
|
BKD
Brookdale Senior Living Inc.
|
Buy |
10.62% |
9.26% |
2024-10-15 |
|
ARWR
Arrowhead Pharmaceuticals, Inc.
|
Buy |
10.46% |
7.64% |
2024-10-15 |
|
VCEL
Vericel Corporation
|
Buy |
9.39% |
-3.37% |
2024-10-15 |
|
CDXS
Codexis, Inc.
|
Buy |
9.65% |
-0.59% |
2024-10-16 |
|
SGMO
Sangamo Therapeutics, Inc.
|
Buy |
9.41% |
-3.09% |
2024-10-16 |
|
VREX
Varex Imaging Corporation
|
Buy |
9.56% |
0% |
2024-10-18 |
|
NKTR
Nektar Therapeutics
|
Buy |
9.56% |
0% |
2024-10-18 |
The percentage of cash held in the portfolio is:
2%
New Assets Added
Assets Removed
| Asset |
Action |
Perf % |
| RDNT |
Sell
All
|
-3.2% |
Assets Rebalanced
None
2024-10-16 00:00:00
: Portfolio change date
| Asset |
Action |
Weight |
PnL |
Entry Date |
|
IRWD
Ironwood Pharmaceuticals, Inc.
|
Buy |
10.07% |
3.05% |
2024-10-03 |
|
ORGO
Organogenesis Holdings Inc.
|
Buy |
10.16% |
3.9% |
2024-10-07 |
|
ARDX
Ardelyx, Inc.
|
Buy |
9.59% |
-1.16% |
2024-10-14 |
|
BKD
Brookdale Senior Living Inc.
|
Buy |
9.73% |
0.33% |
2024-10-15 |
|
ARWR
Arrowhead Pharmaceuticals, Inc.
|
Buy |
9.96% |
2.69% |
2024-10-15 |
|
VCEL
Vericel Corporation
|
Buy |
9.67% |
-0.33% |
2024-10-15 |
|
RDNT
RadNet, Inc.
|
Buy |
9.72% |
0.2% |
2024-10-15 |
|
CDXS
Codexis, Inc.
|
Buy |
9.7% |
0% |
2024-10-16 |
|
SGMO
Sangamo Therapeutics, Inc.
|
Buy |
9.7% |
0% |
2024-10-16 |
The percentage of cash held in the portfolio is:
11.7%
New Assets Added
Assets Removed
None
Assets Rebalanced
None
2024-10-15 00:00:00
: Portfolio change date
| Asset |
Action |
Weight |
PnL |
Entry Date |
|
IRWD
Ironwood Pharmaceuticals, Inc.
|
Buy |
9.93% |
0.7% |
2024-10-03 |
|
ORGO
Organogenesis Holdings Inc.
|
Buy |
9.89% |
0.32% |
2024-10-07 |
|
ARDX
Ardelyx, Inc.
|
Buy |
9.7% |
-0.83% |
2024-10-14 |
|
BKD
Brookdale Senior Living Inc.
|
Buy |
9.78% |
0% |
2024-10-15 |
|
ARWR
Arrowhead Pharmaceuticals, Inc.
|
Buy |
9.78% |
0% |
2024-10-15 |
|
VCEL
Vericel Corporation
|
Buy |
9.78% |
0% |
2024-10-15 |
|
RDNT
RadNet, Inc.
|
Buy |
9.78% |
0% |
2024-10-15 |
The percentage of cash held in the portfolio is:
31.35%
New Assets Added
Assets Removed
None
Assets Rebalanced
None
2024-10-14 00:00:00
: Portfolio change date
| Asset |
Action |
Weight |
PnL |
Entry Date |
|
IRWD
Ironwood Pharmaceuticals, Inc.
|
Buy |
9.86% |
0% |
2024-10-03 |
|
ORGO
Organogenesis Holdings Inc.
|
Buy |
9.83% |
-0.32% |
2024-10-07 |
|
ARDX
Ardelyx, Inc.
|
Buy |
9.79% |
0% |
2024-10-14 |
The percentage of cash held in the portfolio is:
70.52%
New Assets Added
Assets Removed
None
Assets Rebalanced
None
2024-10-11 00:00:00
: Portfolio change date
| Asset |
Action |
Weight |
PnL |
Entry Date |
|
IRWD
Ironwood Pharmaceuticals, Inc.
|
Buy |
9.77% |
-1.17% |
2024-10-03 |
|
ORGO
Organogenesis Holdings Inc.
|
Buy |
9.7% |
-1.95% |
2024-10-07 |
The percentage of cash held in the portfolio is:
80.53%
New Assets Added
None
Assets Removed
| Asset |
Action |
Perf % |
| BCRX |
Sell
All
|
-6.07% |
Assets Rebalanced
None
2024-10-07 00:00:00
: Portfolio change date
| Asset |
Action |
Weight |
PnL |
Entry Date |
|
IRWD
Ironwood Pharmaceuticals, Inc.
|
Buy |
9.88% |
0.94% |
2024-10-03 |
|
BCRX
BioCryst Pharmaceuticals, Inc.
|
Buy |
9.79% |
0% |
2024-10-07 |
|
ORGO
Organogenesis Holdings Inc.
|
Buy |
9.79% |
0% |
2024-10-07 |
The percentage of cash held in the portfolio is:
70.54%
New Assets Added
Assets Removed
None
Assets Rebalanced
None
2024-10-03 00:00:00
: Portfolio change date
| Asset |
Action |
Weight |
PnL |
Entry Date |
|
IRWD
Ironwood Pharmaceuticals, Inc.
|
Buy |
9.8% |
0% |
2024-10-03 |
The percentage of cash held in the portfolio is:
90.2%
New Assets Added
Assets Removed
None
Assets Rebalanced
None
2024-09-26 00:00:00
: Portfolio change date
No Asset in the portfolio
The percentage of cash held in the portfolio is:
100%
New Assets Added
None
Assets Removed
| Asset |
Action |
Perf % |
| NVCR |
Sell
All
|
-11.63% |
Assets Rebalanced
None
2024-09-25 00:00:00
: Portfolio change date
| Asset |
Action |
Weight |
PnL |
Entry Date |
|
NVCR
NovoCure Limited
|
Buy |
8.11% |
-8.98% |
2024-09-06 |
The percentage of cash held in the portfolio is:
91.89%
New Assets Added
None
Assets Removed
| Asset |
Action |
Perf % |
| MYGN |
Sell
All
|
-1.56% |
Assets Rebalanced
None
2024-09-24 00:00:00
: Portfolio change date
| Asset |
Action |
Weight |
PnL |
Entry Date |
|
NVCR
NovoCure Limited
|
Buy |
8.15% |
-8.42% |
2024-09-06 |
|
MYGN
Myriad Genetics, Inc.
|
Buy |
8.74% |
-0.15% |
2024-09-09 |
The percentage of cash held in the portfolio is:
83.11%
New Assets Added
None
Assets Removed
| Asset |
Action |
Perf % |
| ESPR |
Sell
All
|
-10.93% |
Assets Rebalanced
None
2024-09-19 00:00:00
: Portfolio change date
| Asset |
Action |
Weight |
PnL |
Entry Date |
|
ESPR
Esperion Therapeutics, Inc.
|
Buy |
8.57% |
-4.92% |
2024-09-04 |
|
NVCR
NovoCure Limited
|
Buy |
8.54% |
-2.44% |
2024-09-06 |
|
MYGN
Myriad Genetics, Inc.
|
Buy |
9.1% |
5.56% |
2024-09-09 |
The percentage of cash held in the portfolio is:
73.78%
New Assets Added
None
Assets Removed
| Asset |
Action |
Perf % |
| PODD |
Sell
All
|
15.5% |
Assets Rebalanced
None
2024-09-17 00:00:00
: Portfolio change date
| Asset |
Action |
Weight |
PnL |
Entry Date |
|
PODD
Insulet Corporation
|
Buy |
11.32% |
14.42% |
2024-08-29 |
|
ESPR
Esperion Therapeutics, Inc.
|
Buy |
8.68% |
-3.83% |
2024-09-04 |
|
NVCR
NovoCure Limited
|
Buy |
8.72% |
-0.5% |
2024-09-06 |
|
MYGN
Myriad Genetics, Inc.
|
Buy |
8.92% |
3.45% |
2024-09-09 |
The percentage of cash held in the portfolio is:
62.37%
New Assets Added
None
Assets Removed
| Asset |
Action |
Perf % |
| AADI |
Sell
All
|
7.43% |
| TVTX |
Sell
All
|
48.65% |
Assets Rebalanced
None
2024-09-13 00:00:00
: Portfolio change date
| Asset |
Action |
Weight |
PnL |
Entry Date |
|
AADI
Aadi Bioscience, Inc.
|
Buy |
10.3% |
1.14% |
2024-08-27 |
|
PODD
Insulet Corporation
|
Buy |
11.52% |
12.73% |
2024-08-29 |
|
TVTX
Travere Therapeutics, Inc.
|
Buy |
12.23% |
31.25% |
2024-09-04 |
|
ESPR
Esperion Therapeutics, Inc.
|
Buy |
8.91% |
-4.37% |
2024-09-04 |
|
NVCR
NovoCure Limited
|
Buy |
8.69% |
-3.99% |
2024-09-06 |
|
MYGN
Myriad Genetics, Inc.
|
Buy |
8.71% |
-2.15% |
2024-09-09 |
The percentage of cash held in the portfolio is:
39.64%
New Assets Added
None
Assets Removed
| Asset |
Action |
Perf % |
| AGEN |
Sell
All
|
8.41% |
Assets Rebalanced
None
2024-09-12 00:00:00
: Portfolio change date
| Asset |
Action |
Weight |
PnL |
Entry Date |
|
AGEN
Agenus Inc.
|
Buy |
10.59% |
3.11% |
2024-08-23 |
|
AADI
Aadi Bioscience, Inc.
|
Buy |
10.79% |
5.14% |
2024-08-27 |
|
PODD
Insulet Corporation
|
Buy |
11.47% |
11.4% |
2024-08-29 |
|
TVTX
Travere Therapeutics, Inc.
|
Buy |
11.97% |
27.5% |
2024-09-04 |
|
ESPR
Esperion Therapeutics, Inc.
|
Buy |
8.93% |
-4.92% |
2024-09-04 |
|
NVCR
NovoCure Limited
|
Buy |
8.7% |
-4.54% |
2024-09-06 |
|
MYGN
Myriad Genetics, Inc.
|
Buy |
8.74% |
-2.56% |
2024-09-09 |
The percentage of cash held in the portfolio is:
28.8%
New Assets Added
None
Assets Removed
| Asset |
Action |
Perf % |
| APLS |
Sell
All
|
-3.75% |
Assets Rebalanced
None
2024-09-11 00:00:00
: Portfolio change date
| Asset |
Action |
Weight |
PnL |
Entry Date |
|
APLS
Apellis Pharmaceuticals, Inc.
|
Buy |
10.09% |
-1.69% |
2024-08-22 |
|
AGEN
Agenus Inc.
|
Buy |
10.25% |
-0.18% |
2024-08-23 |
|
AADI
Aadi Bioscience, Inc.
|
Buy |
10.43% |
1.71% |
2024-08-27 |
|
PODD
Insulet Corporation
|
Buy |
11.4% |
10.8% |
2024-08-29 |
|
TVTX
Travere Therapeutics, Inc.
|
Buy |
12.55% |
33.75% |
2024-09-04 |
|
ESPR
Esperion Therapeutics, Inc.
|
Buy |
8.87% |
-5.46% |
2024-09-04 |
|
NVCR
NovoCure Limited
|
Buy |
8.53% |
-6.37% |
2024-09-06 |
|
MYGN
Myriad Genetics, Inc.
|
Buy |
8.99% |
0.26% |
2024-09-09 |
The percentage of cash held in the portfolio is:
18.9%
New Assets Added
None
Assets Removed
| Asset |
Action |
Perf % |
| CARA |
Sell
All
|
-18.08% |
Assets Rebalanced
None
2024-09-10 00:00:00
: Portfolio change date
| Asset |
Action |
Weight |
PnL |
Entry Date |
|
APLS
Apellis Pharmaceuticals, Inc.
|
Buy |
10.29% |
0.21% |
2024-08-22 |
|
CARA
Cara Therapeutics, Inc.
|
Buy |
9.28% |
-9.62% |
2024-08-23 |
|
AGEN
Agenus Inc.
|
Buy |
9.63% |
-6.22% |
2024-08-23 |
|
AADI
Aadi Bioscience, Inc.
|
Buy |
10.61% |
3.43% |
2024-08-27 |
|
PODD
Insulet Corporation
|
Buy |
11.03% |
7.2% |
2024-08-29 |
|
TVTX
Travere Therapeutics, Inc.
|
Buy |
12.57% |
33.96% |
2024-09-04 |
|
ESPR
Esperion Therapeutics, Inc.
|
Buy |
8.71% |
-7.1% |
2024-09-04 |
|
NVCR
NovoCure Limited
|
Buy |
8.38% |
-7.98% |
2024-09-06 |
|
MYGN
Myriad Genetics, Inc.
|
Buy |
9.02% |
0.63% |
2024-09-09 |
The percentage of cash held in the portfolio is:
10.49%
New Assets Added
None
Assets Removed
| Asset |
Action |
Perf % |
| ALDX |
Sell
All
|
-6.49% |
Assets Rebalanced
None
2024-09-09 00:00:00
: Portfolio change date
| Asset |
Action |
Weight |
PnL |
Entry Date |
|
APLS
Apellis Pharmaceuticals, Inc.
|
Buy |
10.73% |
3% |
2024-08-22 |
|
CARA
Cara Therapeutics, Inc.
|
Buy |
9.78% |
-6.12% |
2024-08-23 |
|
AGEN
Agenus Inc.
|
Buy |
9.43% |
-9.51% |
2024-08-23 |
|
AADI
Aadi Bioscience, Inc.
|
Buy |
10.89% |
4.57% |
2024-08-27 |
|
PODD
Insulet Corporation
|
Buy |
10.97% |
5.05% |
2024-08-29 |
|
TVTX
Travere Therapeutics, Inc.
|
Buy |
10.89% |
14.37% |
2024-09-04 |
|
ESPR
Esperion Therapeutics, Inc.
|
Buy |
8.59% |
-9.84% |
2024-09-04 |
|
ALDX
Aldeyra Therapeutics, Inc.
|
Buy |
8.97% |
-3.01% |
2024-09-05 |
|
NVCR
NovoCure Limited
|
Buy |
8.65% |
-6.48% |
2024-09-06 |
|
MYGN
Myriad Genetics, Inc.
|
Buy |
9.1% |
0% |
2024-09-09 |
The percentage of cash held in the portfolio is:
2%
New Assets Added
Assets Removed
| Asset |
Action |
Perf % |
| ORGO |
Sell
All
|
-12.72% |
Assets Rebalanced
None
2024-09-06 00:00:00
: Portfolio change date
| Asset |
Action |
Weight |
PnL |
Entry Date |
|
APLS
Apellis Pharmaceuticals, Inc.
|
Buy |
10.24% |
-1.42% |
2024-08-22 |
|
ORGO
Organogenesis Holdings Inc.
|
Buy |
9.69% |
-6.71% |
2024-08-22 |
|
CARA
Cara Therapeutics, Inc.
|
Buy |
9.72% |
-6.41% |
2024-08-23 |
|
AGEN
Agenus Inc.
|
Buy |
9.5% |
-8.59% |
2024-08-23 |
|
AADI
Aadi Bioscience, Inc.
|
Buy |
10.67% |
2.86% |
2024-08-27 |
|
PODD
Insulet Corporation
|
Buy |
11.01% |
5.72% |
2024-08-29 |
|
TVTX
Travere Therapeutics, Inc.
|
Buy |
9.82% |
3.44% |
2024-09-04 |
|
ESPR
Esperion Therapeutics, Inc.
|
Buy |
8.92% |
-6.01% |
2024-09-04 |
|
ALDX
Aldeyra Therapeutics, Inc.
|
Buy |
9.22% |
0% |
2024-09-05 |
|
NVCR
NovoCure Limited
|
Buy |
9.22% |
0% |
2024-09-06 |
The percentage of cash held in the portfolio is:
2%
New Assets Added
Assets Removed
None
Assets Rebalanced
None
2024-09-05 00:00:00
: Portfolio change date
| Asset |
Action |
Weight |
PnL |
Entry Date |
|
APLS
Apellis Pharmaceuticals, Inc.
|
Buy |
9.84% |
-5.21% |
2024-08-22 |
|
ORGO
Organogenesis Holdings Inc.
|
Buy |
9.91% |
-4.59% |
2024-08-22 |
|
CARA
Cara Therapeutics, Inc.
|
Buy |
9.75% |
-6.12% |
2024-08-23 |
|
AGEN
Agenus Inc.
|
Buy |
9.21% |
-11.33% |
2024-08-23 |
|
AADI
Aadi Bioscience, Inc.
|
Buy |
10.67% |
2.86% |
2024-08-27 |
|
PODD
Insulet Corporation
|
Buy |
10.82% |
3.96% |
2024-08-29 |
|
TVTX
Travere Therapeutics, Inc.
|
Buy |
9.93% |
4.69% |
2024-09-04 |
|
ESPR
Esperion Therapeutics, Inc.
|
Buy |
9.44% |
-0.55% |
2024-09-04 |
|
ALDX
Aldeyra Therapeutics, Inc.
|
Buy |
9.21% |
0% |
2024-09-05 |
The percentage of cash held in the portfolio is:
11.21%
New Assets Added
Assets Removed
| Asset |
Action |
Perf % |
| CERS |
Sell
All
|
-11.34% |
| EGRX |
Sell
All
|
-11.35% |
Assets Rebalanced
None
2024-09-04 00:00:00
: Portfolio change date
| Asset |
Action |
Weight |
PnL |
Entry Date |
|
APLS
Apellis Pharmaceuticals, Inc.
|
Buy |
10.08% |
-2.65% |
2024-08-22 |
|
ORGO
Organogenesis Holdings Inc.
|
Buy |
9.99% |
-3.53% |
2024-08-22 |
|
CARA
Cara Therapeutics, Inc.
|
Buy |
10% |
-3.5% |
2024-08-23 |
|
AGEN
Agenus Inc.
|
Buy |
9.38% |
-9.51% |
2024-08-23 |
|
CERS
Cerus Corporation
|
Buy |
9.52% |
-7.98% |
2024-08-27 |
|
AADI
Aadi Bioscience, Inc.
|
Buy |
10.29% |
-0.57% |
2024-08-27 |
|
PODD
Insulet Corporation
|
Buy |
10.5% |
1.11% |
2024-08-29 |
|
EGRX
Eagle Pharmaceuticals, Inc.
|
Buy |
9.3% |
-10.38% |
2024-08-29 |
|
TVTX
Travere Therapeutics, Inc.
|
Buy |
9.47% |
0% |
2024-09-04 |
|
ESPR
Esperion Therapeutics, Inc.
|
Buy |
9.47% |
0% |
2024-09-04 |
The percentage of cash held in the portfolio is:
2%
New Assets Added
Assets Removed
| Asset |
Action |
Perf % |
| ARDX |
Sell
All
|
-11.62% |
| NEOG |
Sell
All
|
-6.34% |
Assets Rebalanced
None
2024-08-29 00:00:00
: Portfolio change date
| Asset |
Action |
Weight |
PnL |
Entry Date |
|
ARDX
Ardelyx, Inc.
|
Buy |
9.64% |
-3.45% |
2024-08-22 |
|
APLS
Apellis Pharmaceuticals, Inc.
|
Buy |
9.57% |
-4.2% |
2024-08-22 |
|
ORGO
Organogenesis Holdings Inc.
|
Buy |
10.34% |
3.53% |
2024-08-22 |
|
CARA
Cara Therapeutics, Inc.
|
Buy |
10.37% |
3.79% |
2024-08-23 |
|
AGEN
Agenus Inc.
|
Buy |
9.33% |
-6.58% |
2024-08-23 |
|
CERS
Cerus Corporation
|
Buy |
9.39% |
-5.88% |
2024-08-27 |
|
AADI
Aadi Bioscience, Inc.
|
Buy |
9.58% |
-4% |
2024-08-27 |
|
NEOG
Neogen Corporation
|
Buy |
9.77% |
-2.15% |
2024-08-28 |
|
PODD
Insulet Corporation
|
Buy |
10.01% |
0% |
2024-08-29 |
|
EGRX
Eagle Pharmaceuticals, Inc.
|
Buy |
10.01% |
0% |
2024-08-29 |
The percentage of cash held in the portfolio is:
2%
New Assets Added
Assets Removed
None
Assets Rebalanced
None
2024-08-28 00:00:00
: Portfolio change date
| Asset |
Action |
Weight |
PnL |
Entry Date |
|
ARDX
Ardelyx, Inc.
|
Buy |
9.55% |
-2.35% |
2024-08-22 |
|
APLS
Apellis Pharmaceuticals, Inc.
|
Buy |
9.72% |
-0.64% |
2024-08-22 |
|
ORGO
Organogenesis Holdings Inc.
|
Buy |
10.16% |
3.89% |
2024-08-22 |
|
CARA
Cara Therapeutics, Inc.
|
Buy |
10.24% |
4.66% |
2024-08-23 |
|
AGEN
Agenus Inc.
|
Buy |
10.07% |
2.93% |
2024-08-23 |
|
CERS
Cerus Corporation
|
Buy |
9.53% |
-2.52% |
2024-08-27 |
|
AADI
Aadi Bioscience, Inc.
|
Buy |
9.38% |
-4% |
2024-08-27 |
|
NEOG
Neogen Corporation
|
Buy |
9.78% |
0% |
2024-08-28 |
The percentage of cash held in the portfolio is:
21.57%
New Assets Added
Assets Removed
None
Assets Rebalanced
None
2024-08-27 00:00:00
: Portfolio change date
| Asset |
Action |
Weight |
PnL |
Entry Date |
|
ARDX
Ardelyx, Inc.
|
Buy |
9.51% |
-0.94% |
2024-08-22 |
|
APLS
Apellis Pharmaceuticals, Inc.
|
Buy |
9.6% |
-0.05% |
2024-08-22 |
|
ORGO
Organogenesis Holdings Inc.
|
Buy |
10.28% |
7.07% |
2024-08-22 |
|
CARA
Cara Therapeutics, Inc.
|
Buy |
10.36% |
7.87% |
2024-08-23 |
|
AGEN
Agenus Inc.
|
Buy |
10.3% |
7.31% |
2024-08-23 |
|
CERS
Cerus Corporation
|
Buy |
9.59% |
0% |
2024-08-27 |
|
AADI
Aadi Bioscience, Inc.
|
Buy |
9.59% |
0% |
2024-08-27 |
The percentage of cash held in the portfolio is:
30.77%
New Assets Added
Assets Removed
None
Assets Rebalanced
None
2024-08-23 00:00:00
: Portfolio change date
| Asset |
Action |
Weight |
PnL |
Entry Date |
|
ARDX
Ardelyx, Inc.
|
Buy |
9.4% |
-5.02% |
2024-08-22 |
|
APLS
Apellis Pharmaceuticals, Inc.
|
Buy |
9.72% |
-1.79% |
2024-08-22 |
|
ORGO
Organogenesis Holdings Inc.
|
Buy |
9.61% |
-2.83% |
2024-08-22 |
|
CARA
Cara Therapeutics, Inc.
|
Buy |
9.9% |
0% |
2024-08-23 |
|
AGEN
Agenus Inc.
|
Buy |
9.9% |
0% |
2024-08-23 |
The percentage of cash held in the portfolio is:
51.48%
New Assets Added
Assets Removed
None
Assets Rebalanced
None
2024-08-22 00:00:00
: Portfolio change date
| Asset |
Action |
Weight |
PnL |
Entry Date |
|
ARDX
Ardelyx, Inc.
|
Buy |
9.8% |
0% |
2024-08-22 |
|
APLS
Apellis Pharmaceuticals, Inc.
|
Buy |
9.8% |
0% |
2024-08-22 |
|
ORGO
Organogenesis Holdings Inc.
|
Buy |
9.8% |
0% |
2024-08-22 |
The percentage of cash held in the portfolio is:
70.6%
New Assets Added
Assets Removed
None
Assets Rebalanced
None
2024-08-19 00:00:00
: Portfolio change date
No Asset in the portfolio
The percentage of cash held in the portfolio is:
100%
New Assets Added
None
Assets Removed
| Asset |
Action |
Perf % |
| CYH |
Sell
All
|
-1.57% |
Assets Rebalanced
None
2024-08-08 00:00:00
: Portfolio change date
| Asset |
Action |
Weight |
PnL |
Entry Date |
|
CYH
Community Health Systems, Inc.
|
Buy |
9.14% |
-7.66% |
2024-07-29 |
The percentage of cash held in the portfolio is:
90.86%
New Assets Added
None
Assets Removed
| Asset |
Action |
Perf % |
| RMD |
Sell
All
|
1.39% |
| RCM |
Sell
All
|
7.14% |
Assets Rebalanced
None
2024-08-06 00:00:00
: Portfolio change date
| Asset |
Action |
Weight |
PnL |
Entry Date |
|
RCM
R1 RCM Inc.
|
Buy |
9.53% |
7.06% |
2024-07-18 |
|
CYH
Community Health Systems, Inc.
|
Buy |
9.33% |
-5.3% |
2024-07-29 |
|
RMD
ResMed Inc.
|
Buy |
9.11% |
3.67% |
2024-07-31 |
The percentage of cash held in the portfolio is:
72.03%
New Assets Added
None
Assets Removed
| Asset |
Action |
Perf % |
| BKD |
Sell
All
|
-5.42% |
| FATE |
Sell
All
|
7.71% |
Assets Rebalanced
None
2024-08-05 00:00:00
: Portfolio change date
| Asset |
Action |
Weight |
PnL |
Entry Date |
|
BKD
Brookdale Senior Living Inc.
|
Buy |
12.18% |
-1.06% |
2024-07-16 |
|
FATE
Fate Therapeutics, Inc.
|
Buy |
14.65% |
19.02% |
2024-07-16 |
|
RCM
R1 RCM Inc.
|
Buy |
9.35% |
7.83% |
2024-07-18 |
|
CYH
Community Health Systems, Inc.
|
Buy |
9.4% |
-1.96% |
2024-07-29 |
|
RMD
ResMed Inc.
|
Buy |
9.2% |
7.5% |
2024-07-31 |
The percentage of cash held in the portfolio is:
45.23%
New Assets Added
None
Assets Removed
| Asset |
Action |
Perf % |
| HQY |
Sell
All
|
-11.82% |
| HCSG |
Sell
All
|
-6.49% |
Assets Rebalanced
None
2024-08-01 00:00:00
: Portfolio change date
| Asset |
Action |
Weight |
PnL |
Entry Date |
|
BKD
Brookdale Senior Living Inc.
|
Buy |
12.19% |
2.25% |
2024-07-16 |
|
FATE
Fate Therapeutics, Inc.
|
Buy |
16.33% |
37.02% |
2024-07-16 |
|
RCM
R1 RCM Inc.
|
Buy |
8.3% |
-1.15% |
2024-07-18 |
|
CYH
Community Health Systems, Inc.
|
Buy |
9.6% |
3.34% |
2024-07-29 |
|
HQY
HealthEquity, Inc.
|
Buy |
9.01% |
-3.09% |
2024-07-29 |
|
HCSG
Healthcare Services Group, Inc.
|
Buy |
8.44% |
-1.12% |
2024-07-30 |
|
RMD
ResMed Inc.
|
Buy |
8.49% |
2.5% |
2024-07-31 |
The percentage of cash held in the portfolio is:
27.63%
New Assets Added
None
Assets Removed
| Asset |
Action |
Perf % |
| PDSB |
Sell
All
|
1.14% |
| OPK |
Sell
All
|
7.58% |
Assets Rebalanced
None
2024-07-31 00:00:00
: Portfolio change date
| Asset |
Action |
Weight |
PnL |
Entry Date |
|
PDSB
PDS Biotechnology Corporation
|
Buy |
8.26% |
-1.7% |
2024-07-11 |
|
OPK
OPKO Health, Inc.
|
Buy |
9.1% |
8.33% |
2024-07-11 |
|
BKD
Brookdale Senior Living Inc.
|
Buy |
12.45% |
3.44% |
2024-07-16 |
|
FATE
Fate Therapeutics, Inc.
|
Buy |
15.88% |
31.88% |
2024-07-16 |
|
RCM
R1 RCM Inc.
|
Buy |
8.39% |
-1% |
2024-07-18 |
|
CYH
Community Health Systems, Inc.
|
Buy |
9.51% |
1.38% |
2024-07-29 |
|
HQY
HealthEquity, Inc.
|
Buy |
9.09% |
-3.16% |
2024-07-29 |
|
HCSG
Healthcare Services Group, Inc.
|
Buy |
8.58% |
-0.43% |
2024-07-30 |
|
RMD
ResMed Inc.
|
Buy |
8.37% |
0% |
2024-07-31 |
The percentage of cash held in the portfolio is:
10.37%
New Assets Added
Assets Removed
| Asset |
Action |
Perf % |
| SMTI |
Sell
All
|
-8.69% |
| CLDX |
Sell
All
|
-12.36% |
Assets Rebalanced
None
2024-07-30 00:00:00
: Portfolio change date
| Asset |
Action |
Weight |
PnL |
Entry Date |
|
PDSB
PDS Biotechnology Corporation
|
Buy |
8.86% |
8.52% |
2024-07-11 |
|
OPK
OPKO Health, Inc.
|
Buy |
8.84% |
8.33% |
2024-07-11 |
|
BKD
Brookdale Senior Living Inc.
|
Buy |
12.2% |
4.37% |
2024-07-16 |
|
FATE
Fate Therapeutics, Inc.
|
Buy |
16.26% |
39.07% |
2024-07-16 |
|
RCM
R1 RCM Inc.
|
Buy |
8.02% |
-2.61% |
2024-07-18 |
|
CLDX
Celldex Therapeutics, Inc.
|
Buy |
8.6% |
-4.26% |
2024-07-26 |
|
SMTI
Sanara MedTech Inc.
|
Buy |
8.62% |
-5.45% |
2024-07-29 |
|
CYH
Community Health Systems, Inc.
|
Buy |
9.27% |
1.77% |
2024-07-29 |
|
HQY
HealthEquity, Inc.
|
Buy |
8.96% |
-1.69% |
2024-07-29 |
|
HCSG
Healthcare Services Group, Inc.
|
Buy |
8.37% |
0% |
2024-07-30 |
The percentage of cash held in the portfolio is:
2%
New Assets Added
Assets Removed
| Asset |
Action |
Perf % |
| PTGX |
Sell
All
|
-7.35% |
Assets Rebalanced
None
2024-07-29 00:00:00
: Portfolio change date
| Asset |
Action |
Weight |
PnL |
Entry Date |
|
PDSB
PDS Biotechnology Corporation
|
Buy |
8.8% |
10.23% |
2024-07-11 |
|
OPK
OPKO Health, Inc.
|
Buy |
8.95% |
12.12% |
2024-07-11 |
|
BKD
Brookdale Senior Living Inc.
|
Buy |
12.09% |
5.69% |
2024-07-16 |
|
FATE
Fate Therapeutics, Inc.
|
Buy |
15.99% |
39.85% |
2024-07-16 |
|
RCM
R1 RCM Inc.
|
Buy |
8.04% |
-0.19% |
2024-07-18 |
|
PTGX
Protagonist Therapeutics, Inc.
|
Buy |
8.46% |
-3.84% |
2024-07-25 |
|
CLDX
Celldex Therapeutics, Inc.
|
Buy |
8.93% |
1.6% |
2024-07-26 |
|
SMTI
Sanara MedTech Inc.
|
Buy |
8.91% |
0% |
2024-07-29 |
|
CYH
Community Health Systems, Inc.
|
Buy |
8.91% |
0% |
2024-07-29 |
|
HQY
HealthEquity, Inc.
|
Buy |
8.91% |
0% |
2024-07-29 |
The percentage of cash held in the portfolio is:
2%
New Assets Added
Assets Removed
| Asset |
Action |
Perf % |
| ATRC |
Sell
All
|
-12.65% |
Assets Rebalanced
None
2024-07-26 00:00:00
: Portfolio change date
| Asset |
Action |
Weight |
PnL |
Entry Date |
|
PDSB
PDS Biotechnology Corporation
|
Buy |
8.93% |
11.93% |
2024-07-11 |
|
OPK
OPKO Health, Inc.
|
Buy |
8.58% |
7.58% |
2024-07-11 |
|
BKD
Brookdale Senior Living Inc.
|
Buy |
11.82% |
3.44% |
2024-07-16 |
|
FATE
Fate Therapeutics, Inc.
|
Buy |
15.87% |
38.82% |
2024-07-16 |
|
ATRC
AtriCure, Inc.
|
Buy |
9.75% |
-7% |
2024-07-17 |
|
RCM
R1 RCM Inc.
|
Buy |
7.98% |
-0.84% |
2024-07-18 |
|
PTGX
Protagonist Therapeutics, Inc.
|
Buy |
8.72% |
-0.76% |
2024-07-25 |
|
CLDX
Celldex Therapeutics, Inc.
|
Buy |
8.78% |
0% |
2024-07-26 |
The percentage of cash held in the portfolio is:
19.57%
New Assets Added
Assets Removed
None
Assets Rebalanced
None
2024-07-25 00:00:00
: Portfolio change date
| Asset |
Action |
Weight |
PnL |
Entry Date |
|
PDSB
PDS Biotechnology Corporation
|
Buy |
8.58% |
6.96% |
2024-07-11 |
|
OPK
OPKO Health, Inc.
|
Buy |
8.63% |
7.58% |
2024-07-11 |
|
BKD
Brookdale Senior Living Inc.
|
Buy |
11.93% |
3.7% |
2024-07-16 |
|
FATE
Fate Therapeutics, Inc.
|
Buy |
15.31% |
33.16% |
2024-07-16 |
|
ATRC
AtriCure, Inc.
|
Buy |
10% |
-5.18% |
2024-07-17 |
|
RCM
R1 RCM Inc.
|
Buy |
8.17% |
0.92% |
2024-07-18 |
|
PTGX
Protagonist Therapeutics, Inc.
|
Buy |
8.84% |
0% |
2024-07-25 |
The percentage of cash held in the portfolio is:
28.53%
New Assets Added
Assets Removed
None
Assets Rebalanced
None
2024-07-23 00:00:00
: Portfolio change date
| Asset |
Action |
Weight |
PnL |
Entry Date |
|
PDSB
PDS Biotechnology Corporation
|
Buy |
9.01% |
10.8% |
2024-07-11 |
|
OPK
OPKO Health, Inc.
|
Buy |
9% |
10.61% |
2024-07-11 |
|
BKD
Brookdale Senior Living Inc.
|
Buy |
11.98% |
2.78% |
2024-07-16 |
|
FATE
Fate Therapeutics, Inc.
|
Buy |
13.67% |
17.22% |
2024-07-16 |
|
ATRC
AtriCure, Inc.
|
Buy |
10.07% |
-5.85% |
2024-07-17 |
|
RCM
R1 RCM Inc.
|
Buy |
8.39% |
2.15% |
2024-07-18 |
The percentage of cash held in the portfolio is:
37.89%
New Assets Added
None
Assets Removed
| Asset |
Action |
Perf % |
| VRDN |
Sell
All
|
13.4% |
Assets Rebalanced
None
2024-07-22 00:00:00
: Portfolio change date
| Asset |
Action |
Weight |
PnL |
Entry Date |
|
VRDN
Viridian Therapeutics, Inc.
|
Buy |
10.24% |
9.54% |
2024-07-02 |
|
PDSB
PDS Biotechnology Corporation
|
Buy |
9.05% |
9.94% |
2024-07-11 |
|
OPK
OPKO Health, Inc.
|
Buy |
9.29% |
12.88% |
2024-07-11 |
|
BKD
Brookdale Senior Living Inc.
|
Buy |
11.94% |
1.19% |
2024-07-16 |
|
FATE
Fate Therapeutics, Inc.
|
Buy |
12.95% |
9.77% |
2024-07-16 |
|
ATRC
AtriCure, Inc.
|
Buy |
10.33% |
-4.47% |
2024-07-17 |
|
RCM
R1 RCM Inc.
|
Buy |
8.47% |
2% |
2024-07-18 |
The percentage of cash held in the portfolio is:
27.73%
New Assets Added
None
Assets Removed
| Asset |
Action |
Perf % |
| ALT |
Sell
All
|
-16.04% |
Assets Rebalanced
None
2024-07-19 00:00:00
: Portfolio change date
| Asset |
Action |
Weight |
PnL |
Entry Date |
|
VRDN
Viridian Therapeutics, Inc.
|
Buy |
10.18% |
9.54% |
2024-07-02 |
|
PDSB
PDS Biotechnology Corporation
|
Buy |
8.98% |
9.66% |
2024-07-11 |
|
ALT
Altimmune, Inc.
|
Buy |
7.17% |
-12.43% |
2024-07-11 |
|
OPK
OPKO Health, Inc.
|
Buy |
9.43% |
15.15% |
2024-07-11 |
|
BKD
Brookdale Senior Living Inc.
|
Buy |
11.92% |
1.59% |
2024-07-16 |
|
FATE
Fate Therapeutics, Inc.
|
Buy |
13% |
10.8% |
2024-07-16 |
|
ATRC
AtriCure, Inc.
|
Buy |
10.49% |
-2.49% |
2024-07-17 |
|
RCM
R1 RCM Inc.
|
Buy |
8.14% |
-1.46% |
2024-07-18 |
The percentage of cash held in the portfolio is:
20.7%
New Assets Added
None
Assets Removed
| Asset |
Action |
Perf % |
| CYH |
Sell
All
|
17.81% |
| WST |
Sell
All
|
-5.09% |
Assets Rebalanced
None
2024-07-18 00:00:00
: Portfolio change date
| Asset |
Action |
Weight |
PnL |
Entry Date |
|
CYH
Community Health Systems, Inc.
|
Buy |
11.12% |
23.12% |
2024-06-28 |
|
VRDN
Viridian Therapeutics, Inc.
|
Buy |
10.43% |
15.37% |
2024-07-02 |
|
PDSB
PDS Biotechnology Corporation
|
Buy |
9.07% |
13.92% |
2024-07-11 |
|
ALT
Altimmune, Inc.
|
Buy |
7.97% |
0.13% |
2024-07-11 |
|
OPK
OPKO Health, Inc.
|
Buy |
8.56% |
7.58% |
2024-07-11 |
|
WST
West Pharmaceutical Services, Inc.
|
Buy |
7.73% |
-1.88% |
2024-07-12 |
|
BKD
Brookdale Senior Living Inc.
|
Buy |
11.66% |
2.25% |
2024-07-16 |
|
FATE
Fate Therapeutics, Inc.
|
Buy |
13.07% |
14.65% |
2024-07-16 |
|
ATRC
AtriCure, Inc.
|
Buy |
10.36% |
-0.91% |
2024-07-17 |
|
RCM
R1 RCM Inc.
|
Buy |
8.03% |
0% |
2024-07-18 |
The percentage of cash held in the portfolio is:
2%
New Assets Added
Assets Removed
| Asset |
Action |
Perf % |
| BHVN |
Sell
All
|
0.3% |
Assets Rebalanced
None
2024-07-17 00:00:00
: Portfolio change date
| Asset |
Action |
Weight |
PnL |
Entry Date |
|
CYH
Community Health Systems, Inc.
|
Buy |
11.03% |
25% |
2024-06-28 |
|
VRDN
Viridian Therapeutics, Inc.
|
Buy |
10.67% |
20.89% |
2024-07-02 |
|
PDSB
PDS Biotechnology Corporation
|
Buy |
9.15% |
17.76% |
2024-07-11 |
|
BHVN
Biohaven Ltd.
|
Buy |
8.15% |
4.86% |
2024-07-11 |
|
ALT
Altimmune, Inc.
|
Buy |
8.42% |
8.29% |
2024-07-11 |
|
OPK
OPKO Health, Inc.
|
Buy |
8.48% |
9.09% |
2024-07-11 |
|
WST
West Pharmaceutical Services, Inc.
|
Buy |
7.6% |
-1.26% |
2024-07-12 |
|
BKD
Brookdale Senior Living Inc.
|
Buy |
11.24% |
0.93% |
2024-07-16 |
|
FATE
Fate Therapeutics, Inc.
|
Buy |
13.03% |
16.97% |
2024-07-16 |
|
ATRC
AtriCure, Inc.
|
Buy |
10.21% |
0% |
2024-07-17 |
The percentage of cash held in the portfolio is:
2%
New Assets Added
Assets Removed
| Asset |
Action |
Perf % |
| RARE |
Sell
All
|
13.6% |
Assets Rebalanced
None
2024-07-16 00:00:00
: Portfolio change date
| Asset |
Action |
Weight |
PnL |
Entry Date |
|
RARE
Ultragenyx Pharmaceutical Inc.
|
Buy |
10.47% |
11.57% |
2024-06-26 |
|
CYH
Community Health Systems, Inc.
|
Buy |
11.15% |
21.88% |
2024-06-28 |
|
VRDN
Viridian Therapeutics, Inc.
|
Buy |
10.17% |
11.2% |
2024-07-02 |
|
PDSB
PDS Biotechnology Corporation
|
Buy |
9.67% |
20.03% |
2024-07-11 |
|
BHVN
Biohaven Ltd.
|
Buy |
8.56% |
6.27% |
2024-07-11 |
|
ALT
Altimmune, Inc.
|
Buy |
8.51% |
5.61% |
2024-07-11 |
|
OPK
OPKO Health, Inc.
|
Buy |
8.73% |
8.33% |
2024-07-11 |
|
WST
West Pharmaceutical Services, Inc.
|
Buy |
7.66% |
-3.96% |
2024-07-12 |
|
BKD
Brookdale Senior Living Inc.
|
Buy |
11.54% |
0% |
2024-07-16 |
|
FATE
Fate Therapeutics, Inc.
|
Buy |
11.54% |
0% |
2024-07-16 |
The percentage of cash held in the portfolio is:
2%
New Assets Added
Assets Removed
| Asset |
Action |
Perf % |
| ACAD |
Sell
All
|
13.54% |
| EGRX |
Sell
All
|
33.26% |
Assets Rebalanced
None
2024-07-12 00:00:00
: Portfolio change date
| Asset |
Action |
Weight |
PnL |
Entry Date |
|
ACAD
ACADIA Pharmaceuticals Inc.
|
Buy |
10.77% |
11.15% |
2024-06-25 |
|
EGRX
Eagle Pharmaceuticals, Inc.
|
Buy |
13.04% |
34.6% |
2024-06-25 |
|
RARE
Ultragenyx Pharmaceutical Inc.
|
Buy |
10.67% |
10.14% |
2024-06-26 |
|
CYH
Community Health Systems, Inc.
|
Buy |
10.95% |
15.94% |
2024-06-28 |
|
VRDN
Viridian Therapeutics, Inc.
|
Buy |
9.26% |
-1.97% |
2024-07-02 |
|
PDSB
PDS Biotechnology Corporation
|
Buy |
9.17% |
10.23% |
2024-07-11 |
|
BHVN
Biohaven Ltd.
|
Buy |
8.73% |
4.89% |
2024-07-11 |
|
ALT
Altimmune, Inc.
|
Buy |
8.54% |
2.67% |
2024-07-11 |
|
OPK
OPKO Health, Inc.
|
Buy |
8.63% |
3.79% |
2024-07-11 |
|
WST
West Pharmaceutical Services, Inc.
|
Buy |
8.24% |
0% |
2024-07-12 |
The percentage of cash held in the portfolio is:
2%
New Assets Added
Assets Removed
None
Assets Rebalanced
None
2024-07-11 00:00:00
: Portfolio change date
| Asset |
Action |
Weight |
PnL |
Entry Date |
|
ACAD
ACADIA Pharmaceuticals Inc.
|
Buy |
10.87% |
7.75% |
2024-06-25 |
|
EGRX
Eagle Pharmaceuticals, Inc.
|
Buy |
13.61% |
34.82% |
2024-06-25 |
|
RARE
Ultragenyx Pharmaceutical Inc.
|
Buy |
10.76% |
6.55% |
2024-06-26 |
|
CYH
Community Health Systems, Inc.
|
Buy |
10.27% |
4.37% |
2024-06-28 |
|
VRDN
Viridian Therapeutics, Inc.
|
Buy |
9.14% |
-7.12% |
2024-07-02 |
|
PDSB
PDS Biotechnology Corporation
|
Buy |
8.67% |
0% |
2024-07-11 |
|
BHVN
Biohaven Ltd.
|
Buy |
8.67% |
0% |
2024-07-11 |
|
ALT
Altimmune, Inc.
|
Buy |
8.67% |
0% |
2024-07-11 |
|
OPK
OPKO Health, Inc.
|
Buy |
8.67% |
0% |
2024-07-11 |
The percentage of cash held in the portfolio is:
10.67%
New Assets Added
Assets Removed
None
Assets Rebalanced
None
2024-07-10 00:00:00
: Portfolio change date
| Asset |
Action |
Weight |
PnL |
Entry Date |
|
ACAD
ACADIA Pharmaceuticals Inc.
|
Buy |
10.89% |
7.87% |
2024-06-25 |
|
EGRX
Eagle Pharmaceuticals, Inc.
|
Buy |
13.67% |
35.49% |
2024-06-25 |
|
RARE
Ultragenyx Pharmaceutical Inc.
|
Buy |
10.7% |
6.02% |
2024-06-26 |
|
CYH
Community Health Systems, Inc.
|
Buy |
10.21% |
3.75% |
2024-06-28 |
|
VRDN
Viridian Therapeutics, Inc.
|
Buy |
9.2% |
-6.59% |
2024-07-02 |
The percentage of cash held in the portfolio is:
45.34%
New Assets Added
None
Assets Removed
| Asset |
Action |
Perf % |
| NVRO |
Sell
All
|
-11.61% |
Assets Rebalanced
None
2024-07-04 00:00:00
: Portfolio change date
| Asset |
Action |
Weight |
PnL |
Entry Date |
|
ACAD
ACADIA Pharmaceuticals Inc.
|
Buy |
10.09% |
-1.83% |
2024-06-25 |
|
EGRX
Eagle Pharmaceuticals, Inc.
|
Buy |
12.62% |
22.77% |
2024-06-25 |
|
RARE
Ultragenyx Pharmaceutical Inc.
|
Buy |
10.37% |
0.9% |
2024-06-26 |
|
CYH
Community Health Systems, Inc.
|
Buy |
10.55% |
5.31% |
2024-06-28 |
|
NVRO
Nevro Corp.
|
Buy |
9.76% |
-2.67% |
2024-07-02 |
|
VRDN
Viridian Therapeutics, Inc.
|
Buy |
9.3% |
-7.27% |
2024-07-02 |
The percentage of cash held in the portfolio is:
37.31%
New Assets Added
None
Assets Removed
| Asset |
Action |
Perf % |
| STAA |
Sell
All
|
1.87% |
Assets Rebalanced
None